Atricure (ATRC) 16.47 $ATRC
Downtrend Call Working As AtriCure Stock Falls 19.5% (ATRC)
Comtex SmarTrend(R) - Fri May 09, 11:05AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 1 month, AtriCure has returned 19.46% as of today's recent price of $15.21.
AtriCure Down 17.6% Since SmarTrend Downtrend Call (ATRC)
Comtex SmarTrend(R) - Fri May 02, 9:46AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 1 month, AtriCure has returned 17.65% as of today's recent price of $15.55.
AtriCure Shares Down 11.2% Since SmarTrend's Sell Call (ATRC)
Comtex SmarTrend(R) - Fri Apr 25, 9:29AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 1 month, AtriCure has returned 11.20% as of today's recent price of $16.77.
AtriCure Reports First Quarter 2014 Financial Results and Updates 2014 Outlook
Business Wire - Thu Apr 24, 3:02PM CDT
--U.S. sales of $18.1 million - up 23.9%
Shares of ATRC Down 15.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 17, 9:55AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 3 weeks, AtriCure has returned 15.50% as of today's recent price of $15.96.
Global Cardiac Prosthetic Devices Market Forecasts & Opportunities 2013 - 2019
M2 - Mon Apr 14, 11:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpd274/cardiac) has announced the addition of the "Global Cardiac Prosthetic Devices Market Forecasts & Opportunities 2013 - 2019" report to their offering. This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter's five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. Sometimes pathological diseases such as diabetes, obesity, hypertension and others might hamper the working mechanism of the valves. Hence, cardiac prosthetics are designed to replace the diseased or damaged natural valves. Artificial valves mainly are of two types namely mechanical heart valves and biological heart valves. Mechanical valves are made up of synthetic materials such as polymers, ceramics and metals. Biologic or the tissue valves are made up of materials from biological origin after modification using physico-chemical treatments. Cardiac diseases are the most common cause of deaths and more people die due to cardiac diseases compared to any other form of disease. According to WHO projection, number of people who will die due to cardiac disease will reach 23.3 million by 2030. Hence, with the rise in number of cardiac diseases the demand for cardiac prosthetic devices is poised to grow at an impressive rate. Mechanical valves dominate the total cardiac devices market followed by tissue valves. Mechanical valves are preferred over tissue valve as they are made from biocompatible material and are durable with long term flexibility. Market Segments - Mechanical Heart Valves - Tissue Heart Valves - Transcatheter Heart Valves - Implantable Pacemaker - External Pacemaker Key Topics Covered: - Preface - Executive Summary - Market Overview - Cardiac Prosthetic Devices Market, by Segments - Cardiac Prosthetic Devices Market, by Geography - Recommendations - Company Profiles - Abbott Laboratories - Abiomed, Inc - AtriCure, Inc - Boston Scientific Corporation - Edward Lifesciences Corporation - Medtronic, Inc - Siemens Healthcare - Sorin Group - St Jude Medical, Inc For more information visit http://www.researchandmarkets.com/research/tpd274/cardiac
12.0% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Thu Apr 10, 9:31AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 2 weeks, AtriCure has returned 11.99% as of today's recent price of $16.62.
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AtriCure to Announce First Quarter 2014 Financial Results
Business Wire - Fri Apr 04, 3:02PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the first quarter of 2014 on Thursday, April 24, 2014.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
101.3% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Mon Mar 24, 9:08AM CDT
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on September 13th, 2013 at $10.06. In approximately 6 months, AtriCure has returned 101.29% as of today's recent price of $20.25.
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
Concise Analysis of the International Energy Based Medical Devices Market
M2 - Fri Mar 14, 4:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/23fbb3/energy_based) has announced the addition of the "Concise Analysis of the International Energy Based Medical Devices Market" report to their offering. This report analyzes the worldwide markets for Energy Based Medical Devices in US$ Million by the following product segments: - Cryotherapy - Electrical - Radiation - Radiofrequency - Ultrasound - Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as: - AngioDynamics, Inc. - ArthroCare Corporation - AtriCure, Inc. - BIOLASE, Inc. - biolitec AG - Biomet, Inc. - Covidien plc Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends, Issues & Drivers 3. Product Overview 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 145 (including Divisions/Subsidiaries - 180) - The United States (76) - Canada (4) - Japan (15) - Europe (54) - France (4) - Germany (20) - The United Kingdom (6) - Italy (6) - Spain (4) - Rest of Europe (14) - Asia-Pacific (Excluding Japan) (21) - Latin America (2) - Middle East (
For more information visit http://www.researchandmarkets.com/research/23...ergy_based About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AtriCure to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Fri Feb 28, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 5, 2014. Management is scheduled to present at 9:20 a.m. Eastern Time.
AtriCure Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 27, 3:01PM CST
--2013 U.S. sales of $62.3 million - up 18.4%
AtriCure Prices Public Offering of Common Stock
Business Wire - Thu Feb 13, 8:02AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced the pricing of its previously announced underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $19.25 per share. AtriCure is offering 3,023,025 shares and selling stockholders are offering 1,226,975 shares of common stock. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 637,500 shares of common stock to cover over-allotments, if any.
AtriCure Announces Commencement of Public Offering of Common Stock
Business Wire - Wed Feb 12, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that AtriCure and certain selling stockholders intend to offer shares of AtriCure common stock in a public offering. AtriCure also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital. AtriCure will not receive any proceeds from the sale of common stock by the selling stockholders.
Downtrend Call Working As AtriCure Stock Falls 19.5% (ATRC)
Comtex SmarTrend(R) - Fri May 09, 11:05AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 1 month, AtriCure has returned 19.46% as of today's recent price of $15.21.
AtriCure Down 17.6% Since SmarTrend Downtrend Call (ATRC)
Comtex SmarTrend(R) - Fri May 02, 9:46AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 1 month, AtriCure has returned 17.65% as of today's recent price of $15.55.
AtriCure Shares Down 11.2% Since SmarTrend's Sell Call (ATRC)
Comtex SmarTrend(R) - Fri Apr 25, 9:29AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 1 month, AtriCure has returned 11.20% as of today's recent price of $16.77.
AtriCure Reports First Quarter 2014 Financial Results and Updates 2014 Outlook
Business Wire - Thu Apr 24, 3:02PM CDT
--U.S. sales of $18.1 million - up 23.9%
Shares of ATRC Down 15.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 17, 9:55AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 3 weeks, AtriCure has returned 15.50% as of today's recent price of $15.96.
Global Cardiac Prosthetic Devices Market Forecasts & Opportunities 2013 - 2019
M2 - Mon Apr 14, 11:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpd274/cardiac) has announced the addition of the "Global Cardiac Prosthetic Devices Market Forecasts & Opportunities 2013 - 2019" report to their offering. This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter's five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. Sometimes pathological diseases such as diabetes, obesity, hypertension and others might hamper the working mechanism of the valves. Hence, cardiac prosthetics are designed to replace the diseased or damaged natural valves. Artificial valves mainly are of two types namely mechanical heart valves and biological heart valves. Mechanical valves are made up of synthetic materials such as polymers, ceramics and metals. Biologic or the tissue valves are made up of materials from biological origin after modification using physico-chemical treatments. Cardiac diseases are the most common cause of deaths and more people die due to cardiac diseases compared to any other form of disease. According to WHO projection, number of people who will die due to cardiac disease will reach 23.3 million by 2030. Hence, with the rise in number of cardiac diseases the demand for cardiac prosthetic devices is poised to grow at an impressive rate. Mechanical valves dominate the total cardiac devices market followed by tissue valves. Mechanical valves are preferred over tissue valve as they are made from biocompatible material and are durable with long term flexibility. Market Segments - Mechanical Heart Valves - Tissue Heart Valves - Transcatheter Heart Valves - Implantable Pacemaker - External Pacemaker Key Topics Covered: - Preface - Executive Summary - Market Overview - Cardiac Prosthetic Devices Market, by Segments - Cardiac Prosthetic Devices Market, by Geography - Recommendations - Company Profiles - Abbott Laboratories - Abiomed, Inc - AtriCure, Inc - Boston Scientific Corporation - Edward Lifesciences Corporation - Medtronic, Inc - Siemens Healthcare - Sorin Group - St Jude Medical, Inc For more information visit http://www.researchandmarkets.com/research/tpd274/cardiac
12.0% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Thu Apr 10, 9:31AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on March 26th, 2014 at $18.89. In approximately 2 weeks, AtriCure has returned 11.99% as of today's recent price of $16.62.
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AtriCure to Announce First Quarter 2014 Financial Results
Business Wire - Fri Apr 04, 3:02PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the first quarter of 2014 on Thursday, April 24, 2014.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
101.3% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Mon Mar 24, 9:08AM CDT
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on September 13th, 2013 at $10.06. In approximately 6 months, AtriCure has returned 101.29% as of today's recent price of $20.25.
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
Concise Analysis of the International Energy Based Medical Devices Market
M2 - Fri Mar 14, 4:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/23fbb3/energy_based) has announced the addition of the "Concise Analysis of the International Energy Based Medical Devices Market" report to their offering. This report analyzes the worldwide markets for Energy Based Medical Devices in US$ Million by the following product segments: - Cryotherapy - Electrical - Radiation - Radiofrequency - Ultrasound - Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as: - AngioDynamics, Inc. - ArthroCare Corporation - AtriCure, Inc. - BIOLASE, Inc. - biolitec AG - Biomet, Inc. - Covidien plc Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends, Issues & Drivers 3. Product Overview 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 145 (including Divisions/Subsidiaries - 180) - The United States (76) - Canada (4) - Japan (15) - Europe (54) - France (4) - Germany (20) - The United Kingdom (6) - Italy (6) - Spain (4) - Rest of Europe (14) - Asia-Pacific (Excluding Japan) (21) - Latin America (2) - Middle East (
For more information visit http://www.researchandmarkets.com/research/23...ergy_based About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. AtriCure to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Fri Feb 28, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 5, 2014. Management is scheduled to present at 9:20 a.m. Eastern Time.
AtriCure Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 27, 3:01PM CST
--2013 U.S. sales of $62.3 million - up 18.4%
AtriCure Prices Public Offering of Common Stock
Business Wire - Thu Feb 13, 8:02AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced the pricing of its previously announced underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $19.25 per share. AtriCure is offering 3,023,025 shares and selling stockholders are offering 1,226,975 shares of common stock. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 637,500 shares of common stock to cover over-allotments, if any.
AtriCure Announces Commencement of Public Offering of Common Stock
Business Wire - Wed Feb 12, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that AtriCure and certain selling stockholders intend to offer shares of AtriCure common stock in a public offering. AtriCure also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital. AtriCure will not receive any proceeds from the sale of common stock by the selling stockholders.
